Lundbeck: Cipralex Falters in Europe
Executive Summary
Lundbeck had appeared well prepared to meet the challenge of losing patent protection on its biggest selling drug, anti-depressant Cipramil. Switching patients to single isomer follow-on Cipralex before generic Cipramil could take hold worked for US marketing partner Forest. But getting follow-on products to market in cost-conscious, skeptical Europe is far harder, as Lundbeck is now learning to its cost.
You may also be interested in...
Novartis' Gleevec Shows Innovation Sells-Even in Europe
While the pharmaceutical industry bemoans the European climate, with its pricing and reimbursement challenges and rationing of access to drugs, Novartis' experience with Gleevec shows that with a truly innovative product that clearly addresses an unmet medical need, it's not impossible to do well in Europe.
Merck Deal Gives Lundbeck US Foothold
Lundbeck's $270 million deal with Merck & Co. to develop and commercialize the Phase III gaboxadol for sleep disorders in the US finally gives the Danish CNS specialist a foothold in the US market. Gaboxadol provides Merck an entry into the burgeoning insomnia market and the deal-the company's largest-ever single-product pact-is indicative of the Big Pharma's growing flexibility and acceptance of external research.
Strakan: Refining Search & Development
The low-risk specialty pharmaceuticals model has never been more fashionable, in part thanks to the success of one of Europe's in-licensing pioneers, Shire. Shire's founder Harry Stratford is now having another go with Strakan, but incorporating R&D far earlier in Strakan's evolution than has been the case at Shire, thereby attempting to address the thorny question of long-term sustainability-one that Shire and other more mature in-licensing firms are currently grappling with.